Why Indian doctors are recommending genome tests before prescriptions

A growing cadre of Indian cardiologists and oncologists in top-tier private hospitals are sidestepping conventional diagnostic protocols, increasingly recommending pharmacogenomic and whole-genome tests before initiating critical treatments. This bold shift, largely absent from standard medical guidelines and insurance coverage, marks a proactive push towards precision medicine, aiming to dramatically reduce adverse drug reactions and improve therapeutic efficacy for a discerning patient base. The impetus stems from compelling evidence of personalized treatment benefits, particularly in cardiology for optimizing antiplatelet drug responses and in oncology for tailoring chemotherapy regimens. While diagnostic giants like MedGenome and Strand Life Sciences are aggressively expanding their offerings to meet this demand, the financial burden falls squarely on patients via out-of-pocket expenses. This private sector-led momentum underscores a regulatory vacuum, with the Indian Council of Medical Research (ICMR) and the Ministry of Health and Family Welfare (MoHFW) only recently initiating preliminary discussions on establishing formal guidelines. The immediate future will see escalating pressure on national health bodies to formulate comprehensive genetic testing guidelines and address reimbursement mechanisms, as the disparity in access grows. Stakeholders must now navigate the delicate balance between fostering medical innovation and ensuring equitable, ethical access to advanced genomic diagnostics, while grappling with the complex data privacy implications of sensitive patient genetic information.